Features: - Antisense application in cell culture and in vivo - including protocols - Antisense in Cancer and Neurobiology - Drug Development with Antisense - new kit including sequence information - Overview: Antisense in clinical trials - Predesigned and validated Antisense (more than 320 publications)
Antisense & RNAi - A Simple Way to Receive Validated Protein Knockdown Results
The parallel application of Antisense and RNAi offers the following advantages: - You get a double check-up of your knockdown results by using two different pathways (RNase H or RISC complex for mRNA degradation) - For verifying your results you only need a specific Antisense and siRNA probe and corresponding negative controls, which is all included in our Antisense & RNAi Kit - No time and cost intensive control experiments - Easy access into in vivo experiments
In Vitro and In Vivo Knockdown of Hsp27 Using Antisense and siRNA Probes in Parallel Approaches
Hsp27 is identified as an independent survival factor in prostate cancer. Increased Hsp27 expression facilitates resistance to androgen withdrawal by blocking apoptotic signals.
Phosphorothioated Hsp27 antisense oligonucleotides and siRNAs reduced Hsp27 levels by 75% and significantly decreased human prostate cancer (PC-3) cell growth (90%) in vitro. Systemic administration of Hsp27 Antisense strongly suppressed PC-3 tumor growth in vivo.
Published Antisense Delivery and Dosing Strategies for In Vivo Applications
Most Antisense experiments produce sufficient inhibition grades without using transfection reagents. Particularly in vivo, sufficient plasma levels are regularly achieved without them.
For your convenience we prepared a comprehensive list describing delivery routes and dosing strategies of diverse antisense in vivo applications from the literature, targeting different tissues like CNS, eye, heart, kidney, lung, tumor etc. Biognostik designed most of the corresponding antisense sequences used in these studies.
Benefit from this list by receiving proven and valuable information for the setup of your own experiments. (For RNAi in vivo applications, please inquire!)
Controls are an indispensable part of every RNAi experiment. Leaders in the field have recommended a standard set of controls to ensure valid RNAi data ("Whither RNAi?" Nature Cell Biology. June 2003. 5(6) p.489-90).
Biognostik's Antisense against TGF beta2 is being developed as a drug candidate by ANTISENSE Pharma. It is now in advanced clinical development. More than 100 patients have been treated with the compound with rather promising results.
Antisense Protocols for In Vitro and In Vivo Protein Knockdown
Biognostik offers a free pdf-copy of the Neurobiology and Oncology chapter of the textbook "Antisense - From Technology to Therapy". These chapters review antisense studies in neurobiology and cancer. The listed protocols may serve as guidelines, which can than be fine-tuned for each individual protein and experimental system.